Heron Therapeutics/$HRTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Heron Therapeutics
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
Ticker
$HRTX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
122
ISIN
US4277461020
Website
HRTX Metrics
BasicAdvanced
$328M
-
-$0.06
1.33
-
Price and volume
Market cap
$328M
Beta
1.33
52-week high
$3.73
52-week low
$1.04
Average daily volume
1.4M
Financial strength
Current ratio
2.403
Quick ratio
1.461
Long term debt to equity
-614.93
Total debt to equity
-622.978
Interest coverage (TTM)
-0.59%
Profitability
EBITDA (TTM)
-1.222
Gross margin (TTM)
64.30%
Net profit margin (TTM)
-5.24%
Operating margin (TTM)
-2.41%
Revenue per employee (TTM)
$1,220,000
Management effectiveness
Return on assets (TTM)
-0.99%
Return on equity (TTM)
25.02%
Valuation
Price to revenue (TTM)
2.215
Price to book
-11.52
Price to tangible book (TTM)
-11.52
Price to free cash flow (TTM)
-13.883
Free cash flow yield (TTM)
-7.20%
Free cash flow per share (TTM)
-15.49%
Growth
Revenue change (TTM)
12.43%
Earnings per share change (TTM)
-89.87%
3-year revenue growth (CAGR)
18.27%
3-year earnings per share growth (CAGR)
-70.97%
10-year earnings per share growth (CAGR)
-32.45%
What the Analysts think about HRTX
Analyst ratings (Buy, Hold, Sell) for Heron Therapeutics stock.
HRTX Financial Performance
Revenues and expenses
HRTX Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Heron Therapeutics stock?
Heron Therapeutics (HRTX) has a market cap of $328M as of July 08, 2025.
What is the P/E ratio for Heron Therapeutics stock?
The price to earnings (P/E) ratio for Heron Therapeutics (HRTX) stock is 0 as of July 08, 2025.
Does Heron Therapeutics stock pay dividends?
No, Heron Therapeutics (HRTX) stock does not pay dividends to its shareholders as of July 08, 2025.
When is the next Heron Therapeutics dividend payment date?
Heron Therapeutics (HRTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Heron Therapeutics?
Heron Therapeutics (HRTX) has a beta rating of 1.33. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.